MIDDLE EAST AND TURKEY IMMUNE THROMBOCYTOPENIC PURPURA (ITP) TREATMENT DRUGS MARKET ANALYSIS

Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs MarketSize and Trends

The Middle East and Turkey immune Thrombocytopenic Purpura (ITP) Treatment Drugs market size was valued at US$ 82.23 million in 2019, and is expected to witness a CAGR of 4.0% over the forecast period (2019 – 2027).

Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market Share (%) Analysis, By Drug Type, 2019

Source: Coherent Market Insights Analysis (2019)

Increasing Drug Approvals & Launches are expected to Drive Growth of the Middle East and Turkey Immune Thrombocytopenic Purpura (ITP) Treatment Drugs Market

Increasing launch of new drugs by key players operating in the ITP treatment drugs market is expected to boost the market growth. Key players are focused on research and development of new drugs to address unmet need of patients with ITP disease. For instance, in June 2019, Dova Pharmaceuticals, Inc. received the U.S. FDA approval for a supplemental New Drug Application (sNDA) to expand the use of the DOPTELET (avatrombopag) drug for treatment of chronic immune thrombocytopenia (ITP) in adults who had a deficient response to previous treatment. Dova Pharmaceuticals, Inc. is expected to launch DOPTELET in Asia Pacific, Middle East, and Africa in 2021.